Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
Summary
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Official title: Prospective Validation Study of Early Cancer Biomarkers in Breath Condensate of Individuals With High-Risk of Lung Cancer Undergoing Low-Dose Computer Tomography Based Screening.
Key Details
Gender
All
Age Range
55 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
3200
Start Date
2023-06-01
Completion Date
2030-12
Last Updated
2026-02-12
Healthy Volunteers
Yes
Conditions
Interventions
Exhaled breath condensate sampling
Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
Blood sampling
A venous blood sample will be taken for further biomarker analysis.
LDCT
LDCT scan will be performed.
Vital signs
Blood pressure, weight, height, pulse, oxygen saturation will be measured.
Spirometry
Spirometry will be performed.
Locations (3)
Masaryk Memorial Cancer Institute
Brno, Czechia
University Hospital
Olomouc, Czechia
General University Hospital in Prague
Prague, Czechia